We recognise that any increase in hospital proactive deprescribing due to the CHARMER approach will have an impact on primary care, after the person is discharged. To understand the effects of CHARMER on primary care, we have established a Primary Care Advisory Group. The group meets twice yearly at key time points in the CHARMER project. The focus of the first meetings have been about how we can make sure that hospital proactive deprescribing is effectively communicated to primary care.
CHARMER PCAG Terms of Reference
For further information about the Primary Care Advisory Group, contact email@example.com.